Evidence map›Paper›PMID 18395508›Full record

ReviewArchives of biochemistry and biophysics2008

Functions of RANKL/RANK/OPG in bone modeling and remodeling.

Brendan F Boyce, Lianping Xing

2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Archives of biochemistry and biophysics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 833 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
833citing papers in PubMed, 6 pooled it
23.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02893891 nacompletednot on this mapstarted 2012, after this paper: background citation

Metabolic Changes of Fat and Bone Tissue After Radical Bariatric Surgery

TypeinterventionalSponsorUniversity Hospital OstravaRan2012 to 2017Enrolled150ConditionsGrade III Obesity, Type 2 Diabetes MellitusArmsLaparoscopic sleeve gastrectomy, Laparoscopic gastric plication, Intragastric balloon, Intragastric balloon implantation
NCT03040765 phase3terminatednot on this mapstarted 2018, after this paper: background citation

Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis

TypeinterventionalSponsorHamad Medical CorporationRan2018 to 2019Enrolled17ConditionsThalassemia Majors (Beta-Thalassemia Major), OsteoporosisArmsDenosumab 60 MG/ML Prefilled Syringe, Zoledronic Acid 5Mg/Bag 100Ml Inj
3 · Its place in the literature

Who cites it

833 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,775 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. General View of Arachidonic Acid (AA) Metabolism.Reviews of physiology, biochemistry and pharmacology · 2027
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Pyroptotic cell-derived factors promote osteoclast differentiation.bioRxiv : the preprint server for biology · 2026
    Article
  19. Article
  20. Article

773 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Brendan F BoyceDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA. brendan_boyce@urmc.rochester.edu
Lianping Xing
University of Rochester Medical Center · US

Funding

Studies on the fate of the OsteoclastR01AR043510 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI BOYCE, BRENDAN F · 1995 to 2025
$8.4M
RANK/NF-KappaB signaling in chondrogenesisR21AR049305 · NIAMS · UNIVERSITY OF ROCHESTER · PI BOYCE, BRENDAN F · 2002 to 2003
$158k
NIAMS NIH HHS R01 AR043510NIAMS NIH HHS R21 AR049305
6 · The paper itself

Abstract

The discovery of the RANKL/RANK/OPG system in the mid 1990s for the regulation of bone resorption has led to major advances in our understanding of how bone modeling and remodeling are regulated. It had been known for many years before this discovery that osteoblastic stromal cells regulated osteoclast formation, but it had not been anticipated that they would do this through expression of members of the TNF superfamily: receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG), or that these cytokines and signaling through receptor activator of NF-kappaB (RANK) would have extensive functions beyond regulation of bone remodeling. RANKL/RANK signaling regulates osteoclast formation, activation and survival in normal bone modeling and remodeling and in a variety of pathologic conditions characterized by increased bone turnover. OPG protects bone from excessive resorption by binding to RANKL and preventing it from binding to RANK. Thus, the relative concentration of RANKL and OPG in bone is a major determinant of bone mass and strength. Here, we review our current understanding of the role of the RANKL/RANK/OPG system in bone modeling and remodeling.

Indexed as

AnimalsBone RemodelingBone ResorptionCell DifferentiationHumansMiceOsteoclastsOsteogenesisOsteoprotegerinRANK LigandReceptor Activator of Nuclear Factor-kappa BSignal TransductionOsteoprotegerinRANK LigandReceptor Activator of Nuclear Factor-kappa B

Identifiers

PMID18395508
PMCPMC2413418
OpenAlexW1975953388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.